Apogee Therapeutics, Inc. APGE Deferred Financing Issuance Costs In Accounts Payable And Accrued Expenses
Deferred Financing Issuance Costs In Accounts Payable And Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept apge:DeferredFinancingIssuanceCostsInAccountsPayableAndAccruedExpenses.
The official record: Apogee Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s deferred financing issuance costs in accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s deferred financing issuance costs in accounts payable and accrued expenses?
- Apogee Therapeutics, Inc. (APGE) reported deferred financing issuance costs in accounts payable and accrued expenses of $7.5K in Q4 2024.
- What does deferred financing issuance costs in accounts payable and accrued expenses mean?
- This represents the portion of costs associated with raising capital that have been accrued but not yet paid in cash at the end of the reporting period. It provides transparency into the total cost of financing activities by capturing liabilities that will result in future cash outflows. Tracking this helps investors reconcile the total cost of capital raises with the actual cash proceeds reported in financing activities.